Drug Approval | May 05, 2026
Lupin receives USFDA approval for generic Ravicti oral liquid
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Keeps Halo Pharma to drive independent growth
The company’s Growth Portfolio delivered $6.2 billion in revenue
Healthcare and consumer wellness leader brings extensive experience in business transformation, commercial strategy and growth leadership to Fertin India
Funds to support product expansion, quick commerce growth, and manufacturing scale-up for holistic period care solutions
The transaction marks a clear portfolio reshuffle for Indoco
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
But acquisition charges drag earnings into loss
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
